biopharmaceutical Industry – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Thu, 20 Jan 2022 18:28:11 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 FSD Pharma Announces Launch of New Corporate Website https://mjshareholders.com/fsd-pharma-announces-launch-of-new-corporate-website/ Thu, 20 Jan 2022 18:28:11 +0000 https://www.cannabisfn.com/?p=2936673

Ryan Allway

January 20th, 2022

News, Psychedelics


New Website Shares FSD’s Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders

TORONTO, January 20, 2022–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company“), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. The new site conveys the Company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. To view the website, please visit www.fsdpharma.com.

“We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeutics,” said Anthony Durkacz, Interim CEO of FSD Pharma. “With some of the greatest minds in neurology and inflammation working together to advance our promising therapeutic compounds, and supported by a strong balance sheet, we believe that we are very well positioned to continue the advancement of our three leading drug candidates: Lucid-MS, Lucid-PSYCH and FSD-PEA. The new look and user-friendly experience of FSD Pharma’s website reflects that, while also serving to educate clinicians, researchers, patients, and investors about our unique approach to delivering ‘Total Brain Health’.”

About FSD Pharma

FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”), a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

Forward-Looking Information

Certain statements contained herein are “forward-looking statements.” Often, but not always, forward-looking statement can be identified by the use of words such as “plans”, “expects”, “expected”, “scheduled”, “estimates”, “intends”, “anticipates”, “hopes”, “planned” or “believes”, or variations of such words and phrases, or states that certain actions, events or results “may”, “could”, “would”, “might”, “potentially” or “will” be taken, occur or be achieved. Forward-looking statements contained in this press release include the comments made with respect to the Company’s normal course issuer bid, advancing the Company’s research and efforts to enhance shareholder value. FSD cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Factors that may cause such material differences include without limitation: the fact that the drug development efforts of both Lucid and FSD BioSciences are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of Lucid and FSD BioSciences may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of Lucid and FSD BioSciences; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid and FSD BioSciences; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of Lucid and FSD BioSciences; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected, or impacted by COVID-19 related issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of Lucid and FSD BioSciences; and other risks. Further information regarding factors that may cause actual results to differ materially are included in the Company’s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR (www.sedar.com) and with the U.S. Securities and Exchange Commission on EDGAR (www.sec.gov) under the heading “Risk Factors.” Any forward-looking statement contained in this release speaks only as of its date. The Company does not undertake to update any forward-looking statements, except to the extent required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005132/en/

Contacts

Zeeshan Saeed, Founder, President and Executive Co-Chairman of the Board, FSD Pharma Inc.
[email protected]
(416) 854-8884
Investor Relations: [email protected][email protected]
www.fsdpharma.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Evogene Reports First Quarter 2021 Financial Results https://mjshareholders.com/evogene-reports-first-quarter-2021-financial-results/ Thu, 27 May 2021 01:08:38 +0000 https://www.cannabisfn.com/?p=2920587

Ryan Allway

May 26th, 2021


REHOVOT, IsraelMay 26, 2021 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announces today its financial results for the first quarter of 2021.

Mr. Ofer Haviv, Evogene’s President and CEO, stated, “A major corporate target for this year and the year following is value creation and its recognition by the capital markets, through Evogene’s subsidiaries. Two main paths to achieve this target in life-science based companies, such as our subsidiaries, are: product advancement and commercialization, and demonstration of their underlying technological advantage.

With respect to product advancement, in 2021-2022, all our subsidiaries have significant milestones for pipeline advancement, and some of them are even expected to reach first product launches. We believe that announcing the achievement of such milestones, as they are reached, will enable the capital markets to properly appreciate the value created by the subsidiaries and will also be reflected in Evogene’s value recognition.

With respect to demonstration of the advantage of the underlying technology, we believe that it can be recognized through the rapid progress of our subsidiaries’ discovery and development pipelines. Moreover, any strategic collaboration entered into by a subsidiary, such as between AgPlenus and Corteva, or equity investment in a subsidiary by a strategic partner, such as Corteva’s investment in Lavie Bio, is a vote of confidence in the unique advantages of our technology.

As previously disclosed, some of our subsidiaries are targeting to achieve additional strategic collaborations during 2021-2022. We expect that such collaborations will enable the capital markets to further recognize the unique technological value of our subsidiaries, thus reflecting on Evogene’s value, as well.

I am pleased to report that both Evogene and our subsidiaries have been progressing in accordance with their plans during the first quarter of 2021. Each of our subsidiaries has a very promising product pipeline, and their activities are aiming to advance the products towards commercialization.”

Q1 2021 main achievements

Biomica

  • Received additional positive pre-clinical results in its immuno-oncology program demonstrating efficacy of its live biotherapeutic product consortium BMC128 in combination with immune-checkpoint-inhibitors, this time in melanoma.

Canonic

  • Entered into agreements for the production and distribution in Israel of Canonic’s medical cannabis products with Tikun Olam-Cannbit Pharmaceuticals to enable the planned launch of Canonic’s first product in 2022.

Lavie Bio

  • Recently appointed Mr. Russ Putland as Vice President Commercial, bringing significant commercial experience to the Lavie Bio management team in preparation for its anticipated product launches starting 2022.

Evogene’s Ag-Seed division

  • Entered a collaboration agreement with a U.S. company, Plastomics, whereby Evogene’s insect control genes, demonstrating new modes of action, will be introduced into soybean, utilizing Plastomics’ disruptive new technology.

“We enthusiastically look forward to continuing our progress, achieving our defined targets, entering into new collaborations, and expanding the use of our technology into new fields of activity,” Mr. Haviv concluded.

Consolidated financial results for the first quarter ended as of March 31, 2021:

Cash position: Evogene maintains a strong financial position for its activities with approximately $70.1 million in consolidated cash, cash related accounts, bank deposits and marketable securities as of March 31, 2021. Approximately $11.8 million of Evogene’s consolidated cash is appropriated to its subsidiary, Lavie Bio.

During the first quarter of 2021, our consolidated net cash usage, excluding $27.1 million of net proceeds raised through an “At the Market Offering” (“ATM”) initiated in January 2021 and concluded during February 2021, was approximately $5.2 million, or $4.0 million, if excluding Lavie Bio. The Company has no bank debt.

In March 2021 we announced a new “ATM” and we had not sold any shares under this offering as of the end of the quarter.

Research and Development (“R&D”) expenses: R&D expenses, which are reported net of grants received, were approximately $4.3 million for the first quarter of 2021 (including a non-cash expense of $0.3 million for amortization of share-based compensation), in comparison to $4.6 million (including a non-cash expense of $0.9 million for amortization of share-based compensation) in the first quarter of 2020. In the first quarter of 2021 the actual R&D expenses slightly decreased, mainly due to a decrease in share-based compensation expenses.

Business Development (“BD”) expenses: BD expenses were approximately $0.6 million for the first quarter of 2021 (including a non-cash expense of $0.1 million for amortization of share-based compensation), in comparison to $1.0 million (including a non-cash expense of $0.7 million for amortization of share-based compensation) in the first quarter of 2020.

General and Administrative (“G&A”) expenses: G&A expenses for the first quarter of 2021 were $1.5 million (including a non-cash expense of $0.1 million for amortization of share-based compensation), in comparison to $1.3 million (including a non-cash expense of $0.3 million for amortization of share-based compensation) in the first quarter of 2020. The increase is mainly attributed to the increase of the costs of directors’ and officers’ insurance, partially offset by a decrease in non-cash expenses of amortization of share-based compensation.

Operating loss:  Operating loss for the first quarter of 2021 was $6.3 million, in comparison to $6.9 million for the first quarter of 2020. The decrease in operating loss during the first quarter is attributed to the increase in revenues from collaboration agreements compared to the first quarter of 2020 and due to the decrease in aforementioned amortization of share-based compensation expenses.

Loss: The loss for the first quarter of 2021 was $7.1 million in comparison to a loss of $7.2 million for the first quarter of 2020. The slight decrease in the loss for the first quarter is attributed to the reduction in operating loss, partially offset by an increase in financing expenses mainly attributed to exchange rate differences and revaluation of pre-funded warrants.

Conference Call & Webcast Details:

Date: May 26, 2021

Time: 9:00 am EST; 16:00 Israel time

Dial-in number: 1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally

Webcast: Available at www.evogene.com

Replay Information: A replay of the conference call will be available approximately two hours following the completion of the call.

To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through May 28, 2021, and an archive of the webcast will be available on the Company’s website.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN), is a leading company in leveraging computational biology to design novel products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. For more information, please visit www.evogene.com

Forward Looking Statements

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. For example, Evogene is using forward-looking statement in this press release when it discusses its expected paths to value creation, its and its’ subsidiaries expected trials, studies, product advancements, commercializations, launches, pipelines, milestones, potential collaborations and other plans for 2021 and 2022, the potential advantages of its technology and its anticipated entry into new fields of activity. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with the applicable securities authority, as well as a result of the impacts of the COVID-19 pandemic. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the COVID-19 pandemic), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact

US Investor Relations:

Aviva Banczewski / Rivka Neufeld

Investor Relations and Public Relations Manager

E: [email protected]

T: +972-8-931-1900

Joseph Green
Edison Group
E: [email protected]
T: +1 646-653-7030

Laine Yonker

Edison Group

E: [email protected]

T: +1 646-653-7035

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands (except share and per share data)

As of March 31,

As of December 31,

2021

2020

Unaudited

Audited

CURRENT ASSETS:

Cash and cash equivalents

$             38,642

$                    46,229

Marketable securities

19,948

Short-term bank deposits 

11,500

2,000

Trade receivables 

219

222

Other receivables and prepaid expenses

2,584

3,372

72,893

51,823

LONG-TERM ASSETS:

Long-term deposits

10

9

Right-of-use-assets

1,882

1,872

Property, plant and equipment, net

2,084

2,072

Intangible assets, net

15,909

16,139

19,885

20,092

$             92,778

$                    71,915

CURRENT LIABILITIES:

Trade payables

$                  993

$                         863

Employees and payroll accruals

2,397

2,535

Operating lease liability

758

777

Liabilities in respect of government grants

144

72

Pre-funded warrants

4,144

Deferred revenues and other advances

26

47

Other payables

1,024

1,238

5,342

9,676

LONG-TERM LIABILITIES:

Operating lease liability

1,592

1,663

Liabilities in respect of government grants

3,740

3,694

5,332

5,357

SHAREHOLDERS’ EQUITY:

Ordinary shares of NIS 0.02 par value:

230

200

  Authorized − 150,000,000 ordinary shares; Issued and
  outstanding – 40,414,229 shares as of March 31, 2021
  and 35,600,088 shares as of December 31, 2020

Share premium and other capital reserve

257,184

225,121

Accumulated deficit

(185,878)

(179,276)

Equity attributable to equity holders of the Company

71,536

46,045

Non-controlling interests

10,568

10,837

Total equity

82,104

56,882

$             92,778

$                    71,915

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share data)

Three months ended

March 31,

 Year ended
December 31,

2021

2020

2020

Unaudited

Audited

Revenues

$               333

$               75

$          1,040

Cost of revenues

271

39

574

Gross profit

62

36

466

Operating expenses:

Research and development, net

4,297

4,587

17,287

Business development

570

970

2,672

General and administrative

1,454

1,337

5,321

Total operating expenses

6,321

6,894

25,280

Operating loss

(6,259)

(6,858)

(24,814)

Financing income

52

137

1,591

Financing expenses

(905)

(487)

(2,951)

Financing expenses, net

(853)

(350)

(1,360)

Loss before taxes on income

(7,112)

(7,208)

(26,174)

Taxes on income

8

6

32

Loss

$         (7,120)

$         (7,214)

$      (26,206)

Attributable to:

Equity holders of the Company

(6,602)

(6,228)

(23,374)

Non-controlling interests

(518)

(986)

(2,832)

$         (7,120)

$         (7,214)

$      (26,206)

Basic and diluted loss per share

$           (0.17)

$           (0.24)

$          (0.83)

Weighted average number of shares used in
   computing basic and diluted loss per share

38,959,623

25,754,297

28,158,779

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

Three months ended

March 31,

 Year ended
December 31,

2021

2020

2020

Unaudited

Audited

Cash flows from operating activities:

Loss

$          (7,120)

$           (7,214)

$      (26,206)

Adjustments to reconcile loss to net cash used in operating
   activities:

Adjustments to the profit or loss items:

Depreciation

330

420

1,792

Amortization of intangible assets

230

233

935

Share-based compensation

531

1,934

4,097

Pre-funded warrants issuance expenses

211

Decrease in accrued bank interest

12

25

64

Net financing expense

886

376

967

Taxes on income

8

6

32

1,997

2,994

8,098

Changes in asset and liability items:

Decrease (increase) in trade receivables

3

11

(150)

Decrease (increase) in other receivables

719

(157)

(1,300)

Increase in long-term deposits

(1)

Increase (decrease) in trade payables

123

(274)

(29)

Increase (decrease) in employees and payroll accruals

(138)

(639)

456

Decrease in other payables

(255)

(212)

(87)

Decrease in deferred revenues and other advances

(21)

(41)

(339)

430

(1,312)

(1,449)

Cash received (paid) during the period for:

Interest received

69

112

294

Interest paid

(57)

(50)

(238)

Taxes paid

(8)

(6)

(13)

Net cash used in operating activities

(4,689)

(5,476)

$      (19,514)

Cash flows from investing activities:

Purchase of property, plant and equipment

(183)

(291)

(682)

Proceeds from sale of marketable securities

201

1,044

2,097

Purchase of marketable securities

(20,281)

Proceeds from (investments in) bank deposits, net

(9,500)

2,500

8,000

Net cash provided by (used in) investing activities

$        (29,763)

$              3,253

$           9,415

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

Three months ended

March 31,

 Year ended
December 31,

2021

2020

2020

Unaudited

Audited

Cash flows from financing activities:

Proceeds from issuance of ordinary shares, net of issuance
expenses

27,108

18,658

Proceeds from issuance of pre-funded warrants

1,989

Proceeds from advances for pre-funded warrants

9

Proceeds from exercise of options

445

59

Repayment of lease liability

(167)

(177)

(639)

Proceeds from government grants

123

175

320

Repayment of government grants

(20)

(22)

Net cash provided by (used in) financing activities

27,489

(2)

20,374

Exchange rate differences – cash and cash equivalent
balances

(624)

(512)

1,206

Increase (decrease) in cash and cash equivalents

(7,587)

(2,737)

11,481

Cash and cash equivalents, at the beginning of the period

46,229

34,748

34,748

Cash and cash equivalents, at the end of the period

$           38,642

$          32,011

$         46,229

Significant non-cash activities

Acquisition of property, plant and equipment

$                64

$                17

$                57

Increase (decrease) of right-of-use asset recognized
with corresponding lease liability

$              162

$                   –

$             (41)

Exercise of options

$                   –

$                   –

$                57

Ordinary shares issuance expenses

$                50

$                   –

$                  –

Logo – https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg

SOURCE Evogene

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board https://mjshareholders.com/former-gw-pharmaceuticals-cfo-joins-beckley-psytechs-board/ Tue, 13 Apr 2021 16:14:21 +0000 https://www.cannabisfn.com/?p=2918020

Ryan Allway

April 13th, 2021

Psychedelics


Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.

Bringing nearly two decades of experience in the pharmaceuticals industry, Adam served as Chief Financial Officer (CFO) for five years at GW Pharmaceuticals, the UK-based drug development company focused on using cannabinoid therapeutics for treating a range of diseases. During this time he oversaw the company’s initial public offering on Nasdaq, and was involved in subsequent fundraisings totalling over $1.4 billion.

Adam went on to serve as UK Managing Director from 2017 until December 2020, where he held joint responsibility for leading GW Pharmaceuticals’ Research and Development programmes. Since 2018, he has also served as Audit Committee Chairman for clinical-stage biopharma NuCana Plc, and has held several senior financial roles across both public and private companies in his 30-year career.

In his role at Beckley Psytech, Adam will be responsible for heading up the company’s Audit Committee and will bring to the Board extensive experience of running major growth businesses in the biopharmaceutical industry.

Adam joins the company at an exciting time following a highly successful USD $18m funding round in December 2020, and UK regulatory approval to begin a ground-breaking clinical trial exploring the effects of low-dose psilocybin for treating a rare and debilitating headache condition known as short-lasting unilateral neuralgiform headache attacks (SUNHA).

Cosmo Feilding Mellen, CEO at Beckley Psytech, says: “Adam brings a wealth of senior-level experience in scaling promising life sciences companies, including leading the highly successful Nasdaq IPO for GW Pharmaceuticals during his time as CFO. His knowledge and experience of developing controlled drugs into FDA-approved pharmaceutical medicines for patients in need is particularly relevant for us, and I’ve no doubt Adam’s stewardship on the board will be invaluable to Beckley Psytech as we continue on our own rapid growth journey.”

Adam George, Independent Director at Beckley Psytech, says: “I am delighted to be joining the Beckley Psytech team at this exciting time. I see so many parallels between GW’s cannabis pharmaceutical development story and Beckley Psytech’s mission to develop a pipeline of pharmaceutical medicines from psychedelic molecules for the benefit of patients, and hope that I can apply my GW experience to help the company continue on its ambitious trajectory.”

 

-Ends-

For more information, please contact:

Four Communications

Anthony Cornwell / Max Gibson / Julia Niedoborek

+44 20 3697 4200

[email protected]

Notes to editors

You can download an image of Adam here.

Beckley Psytech

Founded in 2019, Beckley Psytech is a private company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a pipeline of psychedelic compounds into approved pharmaceutical treatments. Our vision, supplemented by our partnership with the Beckley Foundation, is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients in need around the world suffering with these profoundly debilitating conditions.

www.beckleypsytech.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>